Evaluation of the benefits of sequential addition of leflunomide in patients with polyarticular course juvenile idiopathic arthritis failing standard dose methotrexate

Clinical and Experimental Rheumatology

Volumn 33, Issue 2, 2015, Pages 287-292

  Chickermane, Pranav R ^a   Khubchandani, Raju P ^a  

^a JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Leflunomide; Methotrexate; Polyarticular course juvenile idiopathic arthritis

Indexed keywords

LEFLUNOMIDE; METHOTREXATE; PREDNISOLONE; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; ISOXAZOLE DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; STEROID;

ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE EXACERBATION; DOSE RESPONSE; DRUG EFFECT; DRUG PULSE THERAPY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; GASTRITIS; HUMAN; HYPERTRANSAMINASEMIA; JUVENILE RHEUMATOID ARTHRITIS; LOADING DRUG DOSE; MACROPHAGE ACTIVATION SYNDROME; MAINTENANCE DRUG DOSE; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REMISSION; TREATMENT DURATION; ARTHRITIS, JUVENILE; DRUG COMBINATION; TIME; TREATMENT FAILURE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, JUVENILE; CHILD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; MALE; METHOTREXATE; REMISSION INDUCTION; STEROIDS; TIME FACTORS; TREATMENT FAILURE;

EID: 84929942564     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. LAXER RM, GAZARIAN M: Pharmacology and drug therapy. In CASSIDY JT, PETTY RE (Eds.): Textbook of Pediatric Rheumatology. 4th ed., Philadelphia, WB Saunders Company, 2001: 104.
2. KREMER JM: Methotrexate and leflunomide: biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 1999; 29: 14-26.
3. RUPERTO N, MURRAY KJ, GERLONI V et al.: A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum 2004; 50: 2191-201.
4. GIANNINI EH, RUPERTO N, RAVELLI A, LOVELL DJ, FELSON DT, MARTINI A: Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 1202-9.
5. BEUKELMAN T, PATKAR NM, SAAG KG et al.: 2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011; 63: 465-82.
6. CHERWINSKI HM, COHN RG, CHEUNG P et al.: The immunosuppressant leflunomide inhibits lymphocyte proliferation by inhibiting pyrimidine biosynthesis. J Pharmacol Exp Ther 1995; 275: 1043-9.
7. FOX RI: Mechanism of action of leflunomide in rheumatoid arthritis. J Rheumatol 1998; 53 (Suppl.): 20-6.
8. RUCKEMANN K, FAIRBANKS LD, CARREY EA et al.: Leflunomide inhibits pyrimidine de novo synthesis in mitogen-stimulated T-lymphocytes from healthy humans. J Biol Chem 1998; 273: 21682-91.
9. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 1999: 42: 1322-8.
10. HARRIS ED Jr: The rationale for combination therapy of rheumatoid arthritis based on pathophysiology. J Rheumatol 1996; 44 (Suppl.): 2-4.
11. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate-a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33.
12. COHEN S, SCHIFF M, WEAVER A, TESSER J, BARAF H, MAESTRELLO S: Leflunomide (LEF) as initial therapy with methotrexate (MTX) added for rheumatoid arthritis patients with active disease. Arthritis Rheum 2002; 46 (Suppl.): S352.
13. SILVERMAN E, MOUY R, SPIEGEL L et al.: Leflunomide or methotrexate for juvenile rheumatoid arthritis. N Engl J Med 2005; 352: 1655-66.
14. SILVERMAN E, SPIEGEL L, HAWKINS D et al.: Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis. Arthritis Rheum 2005; 52: 554-62.
15. FOELDVARI I, WIERK A: Effectiveness of leflunomide in patients with juvenile idio-pathic arthritis in clinical practice. J Rheumatol 2010; 37: 1763-7.
16. SEGARRA VT, SANTIN P, CASAS L et al.: One-year observation of leflunomide effectiveness and safety in juvenile idiopathic arthritis: a clinical practice review (preliminary data). Pediatric Rheumatology 2011; 9 (Suppl. 1): P 176.
17. JAHAN A, DEWAN V, YADAV TP: Leflunomide in systemic onset juvenile idiopathic arthritis. Indian Pediatr 2012; 49: 750-2.
18. WALLACE CA, RUPERTO N, GIANNINI EH: Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-4.
19. RAVELLI A, MARTINI A: Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000; 27: 1830-3.